SCHEMBL136952

SCHEMBL136952

CCOC(=O)C=C(C)OCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.58
HCAR2 Q8TDS4 1/20 0.48
ALDH1A1 P00352 5/20 0.48
LMNA P02545 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GLO1 Q04760 1/20 0.41
ALOX15 P16050 1/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SOAT1 P35610 1/20 0.40
MAPT P10636 3/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
TRPA1 O75762 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221523 1.00 NPSR1 (0.58) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL9639948 1.00 NPSR1 (0.58) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL9640847 0.86 NPSR1 (0.54) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL3289399 0.86 NPSR1 (0.54) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL3289401 0.86 NPSR1 (0.54) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL10532252 0.86 ALDH1A1 (0.44) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL11126166 0.84 NPSR1 (0.52) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL11818474 0.82
SCHEMBL6127444 0.82
SCHEMBL17300447 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453675-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2022-09-27 US disclosed
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed
US-10787454-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders BIAL—BioTech Investments, Inc. (PT) 2020-09-29 US disclosed
EP-2838900-B1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
US-20190119283-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2019-04-25 US disclosed
EP-3440083-A1 IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-02-13 EP disclosed
US-10174038-B2 Compounds and methods for antiviral treatment GILEAD SCIENCES, INC. (US) 2019-01-08 US disclosed
US-20180298011-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2018-10-18 US disclosed
US-9957275-B2 Pyrazolo[1,5-A]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2018-05-01 US disclosed
US-9957275-B2 Pyrazolo[1,5-A]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2018-05-01 US disclosed
WO-1996024343-A1 USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION SMITHKLINE BEECHAM CORPORATION (US) 1996-08-15 WO disclosed
WO-1993013104-A1 C.N.S. ACTIVE TRICYCLIC THIENOPYRIDINE DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 1993-07-08 WO disclosed
EP-0327223-B1 ANXIOLYTIC AND ANTIDEPRESSANT TETRAHYDROBENZOTHIENOPYRIDINE DERIVATIVES BEECHAM GROUP PLC (GB) 1993-06-02 EP disclosed
US-5100897-A Hypotensive agents, congestive heart failure, ocular hypertension MERCK & CO., INC. (US) 1992-03-31 US disclosed
US-5093493-A Anxiolytic agents, antidepressants BEECHAM GROUP P.L.C. (GB) 1992-03-03 US disclosed
EP-0419048-A2 Substituted pyrimidinones as angiotensin II antagonists MERCK & CO. INC. (US) 1991-03-27 EP disclosed
EP-0327223-A1 Anxiolytic and antidepressant tetrahydrobenzothienopyridine derivatives BEECHAM GROUP PLC (GB) 1989-08-09 EP disclosed
EP-0126970-A2 Anxiolytic and anti-depressant thienopyridine derivatives BEECHAM GROUP PLC (GB) 1984-12-05 EP disclosed
US-3998873-A ORGANOLEPTICS, PERFUMES, AROMAS INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1976-12-21 US disclosed
US-3950427-A ANTIINFLAMMATORY, ANTIPYRETIC BOEHRINGER INGELHEIM GMBH (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119283-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 NPSR1 3423/4885HCAR2 2716/4885ALDH1A1 1121/4885
US-10787454-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders GBA1, GAA, GBA2 NPSR1 3423/4885HCAR2 2716/4885ALDH1A1 1121/4885
US-11453675-B2 Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders GBA1, GAA, GBA2 NPSR1 3423/4885HCAR2 2716/4885ALDH1A1 1121/4885
US-20180298011-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT TYMP, ZC3HAV1, TYMS NPSR1 3940/4885HCAR2 4165/4885ALDH1A1 1823/4885
US-10174038-B2 Compounds and methods for antiviral treatment ZC3HAV1, SARS1, MAVS NPSR1 4434/4885HCAR2 2882/4885ALDH1A1 3727/4885
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 NPSR1 3423/4885HCAR2 2716/4885ALDH1A1 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.